A mutation of RNA polymerase β' subunit (RpoC) converts heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) into "slow VISA".
Various mutations in the rpoB gene, which encodes the RNA polymerase β subunit, are associated with increased vancomycin (VAN) resistance in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneously VISA (hVISA) strains. We reported that rpoB mutations are also linked to the expression of the recently found "slow VISA" (sVISA) phenotype (M. Saito, Y. Katayama, T. Hishinuma, A. Iwamoto, Y. Aiba, K Kuwahara-Arai, L. Cui, M. Matsuo, N. Aritaka, and K. Hiramatsu, Antimicrob Agents Chemother 58:5024-5035, 2014, http://dx.doi.org/10.1128/AAC.02470-13). Because RpoC and RpoB are components of RNA polymerase, we examined the effect of the rpoC(P440L) mutation on the expression of the sVISA phenotype in the Mu3fdh2*V6-5 strain (V6-5), which was derived from a previously reported hVISA strain with the VISA phenotype. V6-5 had an extremely prolonged doubling time (DT) (72 min) and high vancomycin MIC (16 mg/liter). However, the phenotype of V6-5 was unstable, and the strain frequently reverted to hVISA with concomitant loss of low growth rate, cell wall thickness, and reduced autolysis. Whole-genome sequencing of phenotypic revertant strain V6-5-L1 and comparison with V6-5 revealed a second mutation, F562L, in rpoC. Introduction of the wild-type (WT) rpoC gene using a multicopy plasmid resolved the sVISA phenotype of V6-5, indicating that the rpoC(P440L) mutant expressed the sVISA phenotype in hVISA. To investigate the mechanisms of resistance in the sVISA strain, we independently isolated an additional 10 revertants to hVISA and VISA. In subsequent whole-genome analysis, we identified compensatory mutations in the genes of three distinct functional categories: the rpoC gene itself as regulatory mutations, peptidoglycan biosynthesis genes, and relQ, which is involved in the stringent response. It appears that the rpoC(P440L) mutation causes the sVISA phenotype by augmenting cell wall peptidoglycan synthesis and through the control of the stringent response.
Department of Bacteriology, Faculty of Medicine, Juntendo University, Tokyo, Japan mmatsuo@juntendo.ac.jp.
Miki
M
Matsuo
Department of Bacteriology, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Tomomi
T
Hishinuma
Department of Bacteriology, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Yuki
Y
Katayama
Department of Bacteriology, Faculty of Medicine, Juntendo University, Tokyo, Japan Department of Infection Control Science, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Keiichi
K
Hiramatsu
D002473:Cell Wall / Q000235:genetics / Q000648:ultrastructure; D004269:DNA, Bacterial / Q000235:genetics; D012321:DNA-Directed RNA Polymerases / Q000235:genetics*; D018628:Gene Dosage; D016680:Genome, Bacterial / Q000235:genetics; D046228:Microarray Analysis; D008826:Microbial Sensitivity Tests; D009154:Mutation / Q000235:genetics; D010457:Peptidoglycan / Q000096:biosynthesis / Q000235:genetics; D010641:Phenotype; D010957:Plasmids / Q000235:genetics; D013211:Staphylococcus aureus / Q000187:drug effects / Q000235:genetics*; D020713:Vancomycin Resistance / Q000235:genetics*
D004269:DNA, Bacterial; D010457:Peptidoglycan; C108570:beta' subunit of RNA polymerase; D012321:DNA-Directed RNA Polymerases; C105078:RNA polymerase beta subunit